Evaluation of the Efficacy of Streptococcus Salivarius Evol12® in the Reduction of Recurrent Adenotonsillitis in Children

Recruiting N/A Interventional Study
Recurrent Tonsillitis
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
3 – 11
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
200 (estimated)
Sponsor
Liaquat University of Medical & Health Sciences · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This prospective, multicenter, randomized, double-blind, placebo-controlled, cross-over clinical trial will evaluate the efficacy and safety of Streptococcus salivarius Evol12® (Bactoblis® Evol) in reducing the recurrence and duration of acute febrile adenotonsillitis in children aged 3 to 11 years. Participants will receive either the probiotic or a matching placebo for 3 months, followed by a 7-…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male and female children aged 3 to 11 years. * History of ≥3 documented episodes of acute adenotonsillitis within the previous 12 months, each characterized by fever ≥38°C. * Signed and accepted informed consent from a parent or legal guardian. Exclusion Criteria: * Total ob…
Contacts

Davide Sisti, PhD

+39-0722-303301

davide.sisti@uniurb.it

CONTACT